Serlopitant - Menlo Therapeutics

Drug Profile

Serlopitant - Menlo Therapeutics

Alternative Names: JTS 661; MK-0594; VPD-737

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Epidermolysis Bullosa Research Partnership; Japan Tobacco; Menlo Therapeutics; Merck & Co; Stanford University; Torii Pharmaceutical; Velocity Pharmaceutical Development
  • Class Antipruritics; Antitussives; Cyclopentanes; Isoindoles; Skin disorder therapies; Small molecules; Urologics
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pruritus
  • Phase II Prurigo nodularis
  • Discontinued Alcoholism; Cough; Overactive bladder

Most Recent Events

  • 08 Oct 2018 Discontinued - Phase-II for Cough in United Kingdom (PO)
  • 08 Oct 2018 Discontinued - Phase-II for Cough in USA (PO)
  • 08 Oct 2018 Menlo Therapeutics completes enrolment in phase II trial for Pruritus (associated with Psoriasis) in USA before October 2018 (NCT03343639)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top